Glenn J. Hanna, MD, Dana-Farber Cancer Institute

Dr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.

Glenn J Hanna, MD, provides a brief overview of cutaneous squamous cell carcinoma (cSCC), and discusses the currently available treatment options for patients with advanced cSCC.

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.

Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.

Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.

Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.

A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.